Bristol-Myers Squibb (BMY) Shares Pop as Ipilimumab Reaches Primary Endpoint
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $48.86 -0.27%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
Revenue Growth %: +1.4%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 4.7%
Revenue Growth %: +1.4%
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) shares are popping after-hours today following an announcement that ipilimumab clinical trial met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Shares are up 4.9% post-market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) call put ratio 2 calls to 1 put into quarter results and outlook
- Boeing (BA) Cut To Baa3 From Baa2 By Moody's, Outlook Negative
- HP Inc. (HPQ) Climbs Following Stake by Greenlight Capital
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
